TORONTO – Synaptive Medical Inc. has completed the first round of a new preferred equity investment totaling $25 million led by Guelph-Ontario-based Linamar Corp., which also entered into a manufacturing agreement with Synaptive, and Calgary’s Audible Capital Corp.
BEIJING – Chinese transcatheter heart valve developer Venus Medtech (Hangzhou) Inc. on Tuesday saw its share prices jump around 20% on its debut on the Hong Kong Stock Exchange (HKEX), an excellent start for a prerevenue med-tech IPO.
LONDON – Biotech billionaire Bob Duggan is taking a majority stake in Summit Therapeutics plc, as part of a proposed subscription and placing to raise $50 million. The scheme has to be voted through by shareholders, but assuming it is approved, Duggan will control approximately 73% of Summit’s enlarged share capital. Duggan previously invested $25 million in the company at the start of 2019, and already holds 49% of the stock.
DUBLIN – Immunos Therapeutics AG raised CHF15 million (US$15.2 million) in a series A round to move a novel immuno-oncology platform designed to turn cold tumors hot into early clinical development.
BEIJING – EOC Pharmaceutical Group, of Shanghai, completed a series C financing round, bagging $71 million to advance its lead programs EOC-103 and EOC-315 for breast and gastric cancers. The round was led by Hangzhou Tigermed Consulting Co. Ltd. and its affiliated funds, TF Capital and Yingke PE.